ArticleJGH open : an open access journal of gastroenterology and hepatology2025
Carbon-Ion Radiation Therapy Compared to Surgical Resection for Primary, Solitary, Potentially Resectable Hepatocellular Carcinoma.
Article in JGH open : an open access journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbon-Ion Radiation Therapy Compared to Surgical Resection for Primary, Solitary, Potentially Resectable Hepatocellular Carcinoma.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Carbon-ion radiation therapy (CIRT) is a promising technological innovation for treating hepatocellular carcinoma (HCC). This study aimed to evaluate the effectiveness and safety of CIRT for primary, solitary, potentially resectable HCC in comparison to liver resection (LR). Methods and Results: We retrospectively compared treatment effectiveness and safety between patients treated with CIRT and those who underwent LR for potentially resectable HCC at our institution. The clinical data for the CIRT group were obtained from a prospective observational study carried out at our institution, and additional information was obtained from clinical records. Their data were compared with those of patients who underwent LR during the same period. Twenty-three patients were included in the CIRT group and 41 in the LR group. In the overall cohort, the respective 3-and 5-year overall survival (OS) rates were 86.5% and 65.9% for the CIRT group and 90.2% and 79.7% for the LR group. The OS rates did not significantly differ between the two groups in the propensity score-matched cohort. The 3- and 5-year local control rates after CIRT were 77.0% and 77.0%, respectively. CIRT was associated with elevated albumin-bilirubin (ALBI) scores 3 and 6 months after treatment. Conclusion: CIRT for primary, solitary, potentially resectable HCC was associated with favorable clinical outcomes and satisfactory safety, with an acceptable elevation of the ALBI score. CIRT might achieve a favorable OS comparable to LR for potentially resectable HCC; however, further large-scale, prospective studies are needed for confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.